GSK: successful phase 3 trial with Jemperli

(CercleFinance.com) - On Tuesday GSK reported positive phase 3 results for its immunotherapy Jemperli in the treatment of endometrial cancer.


According to preliminary data, the drug, in combination with chemotherapy, reduced the risk of disease progression or death by 72% in patients with dMMR/MSI status compared to chemotherapy alone.

In the total study population, Jemperli reduced this risk by 36%, a level GSK believes is still clinically meaningful.

Based on these results, the British pharmaceutical company says it plans to submit marketing applications to the health authorities in H1 2023.


Copyright (c) 2023 CercleFinance.com. All rights reserved.